Behavioral Intervention
Stepped Alcohol Intervention for Alcohol-related Liver Disease
Recruiting1 award4 criteria
San Francisco, California
This trial is testing a new way to help people with chronic liver disease who have unhealthy alcohol use. The new treatment includes 3 sessions of motivational interviewing, and referral to addiction medicine if necessary. The trial will measure how well the new treatment works at 6 and 12 months.
Organ Preservation
Cold Preservation vs. Machine Perfusion for Liver Transplants
Recruiting1 award10 criteria
Saint Louis, Missouri
This trial will compare the outcomes of transplanting livers that have been kept alive with a machine after being rejected by other transplant centers, to the outcomes of using livers that have been kept cold.
Probiotics
Commensal Bacteria for Liver Disease
Recruiting1 awardPhase 1
Chicago, Illinois
This trial aims to test the safety and tolerability of a new treatment involving live bacteria in patients with liver disease who have low levels of certain substances in their feces. The treatment involves giving patients a
Popular Filters
Trials for Non-alcoholic Fatty Liver Disease Patients
Procedure
ESG + GLP-1RA for Obesity and Liver Fibrosis
Recruiting1 award8 criteria
Boston, Massachusetts
This trial tests a non-invasive, FDA-approved gastric procedure combined with an FDA-approved weight loss medication to see if it can help people with obesity and liver issues lose weight and improve their liver health.
Veteran-Centered Care for Advanced Liver Disease
Recruiting1 award4 criteria
Little Rock, Arkansas
This trial aims to help Veterans suffering from advanced liver disease by using a whole person, Veteran-centered approach to identify and match them with curative and supportive care. Outcomes of the study will inform how to better help those suffering.
Behavioural Intervention
Transitional Care for Liver Disease
Recruiting1 award
Chicago, Illinois
This trial tests a special program called the Transitional Liver Clinic (TLC) for patients with severe liver disease. The TLC aims to reduce hospital readmissions by offering extra support and care coordination after patients leave the hospital.
Noninvasive SHAPE for Portal Hypertension
Recruiting4 awardsPhase 3
Philadelphia, Pennsylvania
This trial will study if the SHAPE algorithm can accurately estimate portal pressures in patients with various degrees of liver disease, if it can predict the development of ascites and other liver-related events, and if it can be used to monitor treatment response in patients with portal hypertension.
Trials for Fatty Liver Disease Patients
Procedure
ESG + GLP-1RA for Obesity and Liver Fibrosis
Recruiting1 award8 criteria
Boston, Massachusetts
This trial tests a non-invasive, FDA-approved gastric procedure combined with an FDA-approved weight loss medication to see if it can help people with obesity and liver issues lose weight and improve their liver health.
Veteran-Centered Care for Advanced Liver Disease
Recruiting1 award4 criteria
Little Rock, Arkansas
This trial aims to help Veterans suffering from advanced liver disease by using a whole person, Veteran-centered approach to identify and match them with curative and supportive care. Outcomes of the study will inform how to better help those suffering.
Behavioural Intervention
Transitional Care for Liver Disease
Recruiting1 award
Chicago, Illinois
This trial tests a special program called the Transitional Liver Clinic (TLC) for patients with severe liver disease. The TLC aims to reduce hospital readmissions by offering extra support and care coordination after patients leave the hospital.
Noninvasive SHAPE for Portal Hypertension
Recruiting4 awardsPhase 3
Philadelphia, Pennsylvania
This trial will study if the SHAPE algorithm can accurately estimate portal pressures in patients with various degrees of liver disease, if it can predict the development of ascites and other liver-related events, and if it can be used to monitor treatment response in patients with portal hypertension.
Phase 3 Trials
Noninvasive SHAPE for Portal Hypertension
Recruiting4 awardsPhase 3
Philadelphia, Pennsylvania
This trial will study if the SHAPE algorithm can accurately estimate portal pressures in patients with various degrees of liver disease, if it can predict the development of ascites and other liver-related events, and if it can be used to monitor treatment response in patients with portal hypertension.
Thyroid Hormone Receptor Agonist
Resmetirom for Non-alcoholic Fatty Liver Disease
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is studying the safety and tolerability of Resmetirom, a pill taken regularly. It involves patients who are already using this medication. Resmetirom helps manage certain health conditions by targeting specific parts of the body and has shown to reduce liver fat in patients with non-alcoholic steatohepatitis (NASH) in previous studies.
Growth Factor
Efruxifermin for NASH
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing a medication called efruxifermin (EFX) to see if it can help people with specific liver conditions. These conditions are hard to treat with current methods. EFX aims to improve liver health by reducing inflammation and fat buildup in the liver.
Antisense Oligonucleotide
Fazirsiran for Alpha-1 Antitrypsin Deficiency
Recruiting2 awardsPhase 3
Birmingham, Alabama
"This trial aims to determine if fazirsiran is safe for long-term use in individuals with liver disease caused by a specific protein. Participants who were part of previous fazirsiran studies can continue in this
siRNA
Fazirsiran for Alpha-1 Antitrypsin Deficiency
Recruiting1 awardPhase 3
San Antonio, Texas
This trial is testing fazirsiran, a drug that may reduce liver scarring and improve liver health, in patients with liver fibrosis. The drug works by decreasing harmful proteins and reducing inflammation in the liver.
Trials With No Placebo
Behavioral Intervention
Alcohol Treatment Engagement for Liver Disease
Recruiting1 award
Ann Arbor, Michigan
"This trial aims to determine if offering personalized alcohol treatment options to patients with alcohol-related liver disease will help them to better engage with treatment and address any misunderstandings they may have."
Procedure
ESG + GLP-1RA for Obesity and Liver Fibrosis
Recruiting1 award8 criteria
Boston, Massachusetts
This trial tests a non-invasive, FDA-approved gastric procedure combined with an FDA-approved weight loss medication to see if it can help people with obesity and liver issues lose weight and improve their liver health.
Veteran-Centered Care for Advanced Liver Disease
Recruiting1 award4 criteria
Little Rock, Arkansas
This trial aims to help Veterans suffering from advanced liver disease by using a whole person, Veteran-centered approach to identify and match them with curative and supportive care. Outcomes of the study will inform how to better help those suffering.
Behavioural Intervention
Transitional Care for Liver Disease
Recruiting1 award
Chicago, Illinois
This trial tests a special program called the Transitional Liver Clinic (TLC) for patients with severe liver disease. The TLC aims to reduce hospital readmissions by offering extra support and care coordination after patients leave the hospital.
Trials Offering Remuneration
RNAi Therapeutics
ALN-PNP for Healthy Subjects
Recruiting0 awardsPhase 1
Marrero, Louisiana
This trial is testing a new drug called ALN-PNP on healthy people and those with a specific liver condition (NAFLD) and gene variant. The goal is to see if the drug is safe, tolerable, and effective in reducing liver fat. Researchers are also studying how the body processes the drug.
Procedure
MDMA for Liver Disease
Recruiting1 awardPhase 1
Knoxville, Tennessee
This trial studies how people with liver problems process MDMA compared to those with healthy livers. MDMA increases brain chemicals to improve mood and communication, which can make therapy sessions more effective for PTSD. The study will help determine if dosage adjustments are needed for people with liver issues. MDMA, also known as Ecstasy, has been used effectively to treat PTSD.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.